CERo Therapeutics Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Ehrlich
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 201 Haskins Way South San Francisco CA United States of America 94080
- IPO Date
- Nov 30, 2021
- CIK
- 0001870404
- Website
- cero.bio
- Similar Companies
- Business
- CERo Therapeutics Holdings, Inc. (CERO) is a clinical-stage immunotherapy company that develops engineered T cell therapeutics utilizing chimeric engulfment receptor T (CER-T) cells for the treatment of hematologic malignancies and solid tumors; its lead product candidate, CER-1236, is an autologous T cell therapy targeting an "Eat Me" signal upregulated on B cell and myeloid tumors in hematologic indications, with additional preclinical applications in solid tumors. Founded in 2021 and headquartered in South San Francisco, California, the company operates a novel platform that integrates innate and adaptive immune mechanisms into single T cells to enhance tumor clearance beyond traditional CAR-T therapies. Recent developments include FDA clearance of its Investigational New Drug application for CER-1236 in acute myeloid leukemia in November 2024, with clinical trials anticipated to commence in early 2025 at sites including MD Anderson Cancer Center; an $8 million securities purchase agreement in April 2025 to fund IND allowances, site activations, and Nasdaq compliance efforts; and a new common stock purchase agreement in December 2025 with Keystone Capital Partners, LLC, enabling up to $14.6 million in additional funding to support ongoing operations and a broad pipeline expansion.
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
CERo Therapeutics Provides Shareholder Update
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
CERo Therapeutics Announces Trading on OTCQB Market
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
Top 3 Health Care Stocks You'll Regret Missing In Q3